SCIENTIFIC BACKGROUND

PROS1

Category:

SCIENTIFIC BACKGROUND

Deficiency of active protein S (protein S activity <60%) leads to decreased anticoagulant activity. Protein S is a vitamin K-dependent protein that acts as a cofactor to activated protein C to accelerate the inactivation of coagulation factors Va and VIIIa. Normally, approximately 60% of protein S is present in a complex with the C4b-binding protein, and only free protein S is available as a cofactor for activated protein C. Protein S deficiency is associated with an increased tendency to have venous thrombosis from the 1st to 4th decade of life. Congenital protein S deficiency is classified as follows:

 

  • Type I: quantitative defect, decreased total and free protein S and protein S activity
  • Type II: qualitative defect, decreased protein S activity with a normal concentration of free and total protein S
  • Type III: quantitative defect, decreased free protein S and protein S activity with a normal plasma concentration of total protein S

 

The expression of the clinical phenotype and the age of onset of the disease is influenced by the type and localization of variants in the PROS1 gene. Homozygous or combined heterozygous protein S deficiency is rare and often leads to perinatal purpura fulminans or massive thrombosis with lethal outcomes. Usually, these patients have protein S activity of <5%. It is important to distinguish this from acquired protein S deficiency, which often occurs in association with inflammation, sepsis, burns, polytrauma, vitamin K deficiency, or major surgery. The use of ovulation inhibitors also lowers protein S activity, so in these cases, the lower limit of the normal range for protein S activity is 50%. Molecular genetic testing can detect causative variants in over 60% of patients with suspected congenital protein S deficiency. This corresponds to 1-2% of all patients with deep vein thrombosis. Larger deletions of single exons or more frequently of the entire gene account for approximately 2-5% of all variants. These can be analyzed by MLPA.

 

References

Alhenc-Gelas et al. 2016, Thromb Haemost 115:570 / Klostermeier et al. 2015, Thromb Haemost 113:426 / Duebgen et al. 2012, Am J Clin Pathol 137(2):178 / Pintao et al. 2010, Hum Genet 127:121 / ten Kate et al. 2008, Hum Mutat 29:939 / Yin et al. 2007, Throm Haemost 98:783 / ten Kate et al 2006, Haematologica 91:1151

GENES

PROS1

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Every year on April 25th, DNA Day celebrates the discovery of DNA’s double helix and the advances we’ve made in understanding genetics. D...

Read more

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f...

Read more

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced ...

Read more

Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso...

Read more

Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co...

Read more

The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study...

Read more

Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a...

Read more

Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area...

Read more

February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th...

Read more

Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor...

Read more